** daily **
** weekly **
** daily **
** weekly **
Description
OXiGENE, Inc. is a clinical-stage, biopharmaceutical company developing novel therapeutics primarily to treat cancer. The Company primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival, and also are associated with visual impairment in a number of ophthalmological diseases and conditions. The Company’s lead compound, ZYBRESTAT is a reversible tubulin binding agent that works by disrupting the network of abnormal blood vessels, or vasculature, within solid tumors, also referred to as vascular disruption. The Company is pursuing development of OXi4503, a second-generation, dual-mechanism VDA, as a treatment for certain solid tumor types and for the treatment of myeloid leukemias, which also represent orphan indications.
Address
Suite 210, 701 Gateway Blvd
SOUTH SAN FRANCISCO, CA 94080
United States
SOUTH SAN FRANCISCO, CA 94080
United States
Website :
www.oxigene.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | - | -5178.85% |
| Operating margin | - | -5174.36% |
| EBITD margin | - | -5083.33% |
| Return on average assets | -98.38% | -97.91% |
| Return on average equity | -281.99% | -121.10% |
| Employees | 7 |
No comments:
Post a Comment